Australia markets closed

Supernus Pharmaceuticals, Inc. (SUPN)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
30.08-0.02 (-0.07%)
At close: 04:00PM EDT
30.08 0.00 (0.00%)
After hours: 04:02PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 1.65B
Enterprise value 1.44B
Trailing P/E 1.50k
Forward P/E 20.16
PEG ratio (5-yr expected) N/A
Price/sales (ttm)2.75
Price/book (mrq)1.79
Enterprise value/revenue 2.37
Enterprise value/EBITDA 15.98

Trading information

Stock price history

Beta (5Y monthly) 0.99
52-week change 3-17.52%
S&P500 52-week change 323.57%
52-week high 338.08
52-week low 321.99
50-day moving average 331.52
200-day moving average 329.08

Share statistics

Avg vol (3-month) 3396.18k
Avg vol (10-day) 3319.53k
Shares outstanding 554.97M
Implied shares outstanding 654.97M
Float 847.74M
% held by insiders 15.02%
% held by institutions 1107.78%
Shares short (15 Apr 2024) 44.68M
Short ratio (15 Apr 2024) 410.84
Short % of float (15 Apr 2024) 412.88%
Short % of shares outstanding (15 Apr 2024) 48.55%
Shares short (prior month 15 Mar 2024) 44.92M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin 0.22%
Operating margin (ttm)11.56%

Management effectiveness

Return on assets (ttm)0.56%
Return on equity (ttm)0.15%

Income statement

Revenue (ttm)607.52M
Revenue per share (ttm)11.14
Quarterly revenue growth (yoy)-1.80%
Gross profit (ttm)N/A
EBITDA 98.26M
Net income avi to common (ttm)1.32M
Diluted EPS (ttm)0.02
Quarterly earnings growth (yoy)-95.40%

Balance sheet

Total cash (mrq)254.87M
Total cash per share (mrq)4.66
Total debt (mrq)41.53M
Total debt/equity (mrq)4.51%
Current ratio (mrq)1.70
Book value per share (mrq)16.84

Cash flow statement

Operating cash flow (ttm)111.08M
Levered free cash flow (ttm)161.71M